About this trial
Age-related macular degeneration (AMD), is a debilitating eye disease that causes a loss of central vision. The prevalence of AMD increases exponentially with age and causes a significant impact through both medical expenses and the social and economic costs associated with vision loss. AMD is the global leading cause of blindness among people over the age of 60. Detection of this eye disease at early stages coupled with prompt treatment can prevent vision loss; however, modern diagnosis methods are ineffective at diagnosis of AMD before vision loss occurs. While a range of available treatment options has been effective at slowing vision loss due to AMD, no treatment exists which can recover lost vision. The investigators propose to apply tools developed in quantum information science to diagnose AMD before vision has been affected, drastically improving health outcomes for patients with AMD.
Eligibility criteria
Qualifiers
Participants who are clinically diagnosed with a vision disease affecting their macula
Older adults who are matched for age.
Participants who are clinically diagnosed with glaucoma
Participants who have normal vision.
Disqualifiers
Participants with any additional eye diagnosis or condition
Trial design
Treatments tested in this trial
- Structured Light Imaging Microscopy
Treatment groups
Sponsors and collaborators
Centre for Eye and Vision Research
Lead sponsor
University of Waterloo
Collaborator
The Hong Kong Polytechnic University
Collaborator